Caspofungin

Generic Name
Caspofungin
Brand Names
Cancidas, Cancidas (previously Caspofungin MSD)
Drug Type
Small Molecule
Chemical Formula
C52H88N10O15
CAS Number
162808-62-0
Unique Ingredient Identifier
F0XDI6ZL63
Background

Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.

Indication

For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Associated Conditions
Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Oropharyngeal Candidiasis, Peritonitis, Pleural space infections
Associated Therapies
-
Clinical Trials
Related News

COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis

Phase 4
Completed
Conditions
Invasive Aspergillosis
First Posted Date
2006-06-07
Last Posted Date
2015-07-09
Lead Sponsor
Gilead Sciences
Target Recruit Count
30
Registration Number
NCT00334412
Locations
🇫🇷

Gilead Sciences, Paris, France

Prophylaxis With Caspofungin in High-Risk Liver Transplantation

First Posted Date
2006-06-06
Last Posted Date
2007-04-13
Lead Sponsor
Grupo de Estudio de Infecciones en Transplantados
Target Recruit Count
70
Registration Number
NCT00333645
Locations
🇪🇸

Hospital Ramon y Cajal, Madrid, Spain

🇪🇸

Hospital Universitario La Fe, Valencia, Spain

🇪🇸

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain

and more 10 locations

A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation

First Posted Date
2005-09-07
Last Posted Date
2008-01-16
Lead Sponsor
University Hospital Muenster
Target Recruit Count
75
Registration Number
NCT00148148
Locations
🇩🇪

KKS Münster University Hospital, Münster, NRW, Germany

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

Phase 3
Completed
Conditions
Candidiasis
Candidemia
Interventions
Drug: Micafungin
Drug: Caspofungin
First Posted Date
2005-03-08
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
611
Registration Number
NCT00105144

Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units

Phase 3
Completed
Conditions
Candidiasis
First Posted Date
2004-12-20
Last Posted Date
2008-03-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
1200
Registration Number
NCT00099775
Locations
🇺🇸

National Cancer Institute (NCI), Bethesda, Maryland, United States

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

Phase 3
Terminated
Conditions
Candidiasis
Interventions
Other: Placebo
Drug: Caspofungin
First Posted Date
2004-11-03
Last Posted Date
2014-12-05
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1200
Registration Number
NCT00095316
Locations
🇺🇸

Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance, California, United States

🇺🇸

Loyola University - Emergency Facility, Maywood, Illinois, United States

🇺🇸

Cooper University Hospital - Infectious Diseases, Camden, New Jersey, United States

and more 23 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy